Research & Clinical Starting Material

Human Leukopaks for Research & Clinical Applications

CGT Global supplies fresh, cryopreserved, mobilized, and disease-state leukopaks for research and cell therapy development, with GMP leukopak options for clinical manufacturing programs.

Source human leukapheresis starting material for PBMC isolation, T-cell and NK-cell research, and custom cell processing. Share your donor criteria, required quantity, and timeline to discuss the right product for your project.

Compare Leukopak Options

Available Products

Browse Human Leukopaks

Explore leukopak products by format, collection approach, and intended use. Select a product to review its available options, specifications, and ordering details. For a specific donor profile or collection schedule, request a project-specific quote.

Choose Your Starting Material

Which Leukopak Is Right for Your Workflow?

Start with the cells you need, then consider processing, scheduling, donor requirements, and intended use. Fresh and cryopreserved describe the product format; mobilized, disease-state, and GMP describe other characteristics. These options can overlap.

Leukopak Options at a Glance
Option When to Consider It What to Confirm
Fresh Leukopaks Time-sensitive workflows with processing coordinated around collection and delivery. Collection date, delivery window, cell quantity, and receiving-lab readiness.
Cryopreserved Leukopaks Studies that need stored material and flexibility in experiment scheduling. Available lots, storage and thawing instructions, and post-thaw specifications.
Mobilized Leukopaks Projects requiring mobilized starting material, including CD34+ hematopoietic stem and progenitor cell workflows. Mobilization regimen, target population, testing, and fresh or cryopreserved format.
Disease-State Leukopaks Research requiring donors with defined clinical characteristics. Diagnosis, treatment history, eligibility criteria, documentation, and availability.
GMP Leukopaks Programs with defined quality and documentation requirements for manufacturing starting material. Intended use, donor eligibility, testing, traceability, and program-specific requirements.

Fresh or Cryopreserved

Plan Your Collection Around Your Experiment

Fresh Leukopaks

Fresh leukopaks are an option when your team can coordinate cell processing with a scheduled collection and delivery. CGT Global collects fresh leukopaks from consented donors at FDA-registered collection clinics.

Discuss the target cell population, required quantity, donor criteria, and shipping destination before scheduling. Align the delivery window with your laboratory’s receiving and processing capacity.

Explore Fresh Leukopaks →

Cryopreserved Leukopaks

Cryopreserved leukopaks give research teams an option for planning experiments around stored material. Review the available product and donor options against your study requirements.

Confirm storage conditions, thawing instructions, and relevant post-thaw performance specifications. Fresh viability and post-thaw viability describe different measurements and should be evaluated separately.

Explore Cryopreserved Leukopaks →

Need help choosing a format? Share your assay, target population, required quantity, and experiment schedule. We can help evaluate available sourcing and processing options.

Project-Specific Sourcing

Mobilized, Disease-State & GMP Leukopaks

Some programs need more than a standard healthy-donor collection. Explore specialized leukopak options and discuss the requirements that matter to your study or manufacturing workflow.

Stem & Progenitor Workflows

Mobilized Leukopaks

Mobilization increases the circulation of hematopoietic stem and progenitor cells before collection. CGT Global offers options using G-CSF, plerixafor (PLX), or a combination.

Discuss the regimen, target CD34+ cell requirements, collection plan, and product format with our team.

Explore Mobilized Leukopaks →

Clinically Defined Donors

Disease-State Leukopaks

Support disease-focused research with leukapheresis material sourced against study-specific donor criteria.

Provide the diagnosis, relevant clinical history, treatment criteria, and testing needs so our team can evaluate feasibility and availability.

Explore Disease-State Options →

Manufacturing Starting Material

GMP Leukopaks

Explore GMP leukopak options for programs with defined sourcing, quality, traceability, and documentation requirements.

Review intended use and required specifications with our team to determine the appropriate starting material for your program.

Explore GMP Leukopaks →

The Right Donor for Your Study

Build Donor Criteria Into Your Sourcing Plan

Donor characteristics can influence cell composition and downstream results. CGT Global can evaluate requests for donor demographics, HLA typing, CMV status, clinical characteristics, and other study-specific requirements.

For longitudinal or larger-scale projects, ask about recallable donors and repeat collections. Availability, eligibility, and scheduling are evaluated for each request.

Define essential criteria early so the collection and testing plan supports your research question.

Discuss Donor Requirements

Donor Demographics

Explore Donor Characteristics for Your Study

Age, sex, ethnicity, and CMV status may be relevant to donor selection. Share the characteristics required by your protocol so our team can evaluate available sourcing options.

CGT Global donor demographics graphic with charts for age, gender, ethnicity, and CMV-IgG status.
Published donor-demographics overview. The distributions shown do not indicate current inventory or guarantee availability of a particular donor profile. Contact our team for current options and study-specific criteria.
View Donor Demographics at Full Size →

Know Your Starting Material

Review Quality, Testing & Product Documentation

CGT Global’s fresh and cryopreserved leukopak product pages describe collections from consented donors at FDA-registered clinics. Select the product and quality requirements that fit your intended use, then review the applicable specifications and documentation.

Cell Quantity & Composition

Review the specified cell count, collection format, and available characterization. Total nucleated cell count is different from the number of PBMCs or a specific subset such as CD3+ or CD34+ cells.

Viability & Processing

Confirm when viability is measured, how it is assessed, and whether a value applies before freezing or after thawing. Discuss handling, isolation, and assay requirements before ordering.

Donor Testing & Records

Review the testing panel, donor information, traceability, and documentation available for the selected product. Additional requirements should be defined during project planning.

Explore the Publications Library Request Product Documentation

Leukopak Characterization

Leukopak Cell Counts & Representative Flow Data

Review CGT Global’s published leukopak figures for additional context on cell counts, mobilization, and selected cell characterization. Discuss the specifications applicable to your selected product with our team before ordering.

Average Leukopak Volume & Cell Count

Average leukopak volume of 185.17 mL and total nucleated cell count of 15.07 billion; standard deviations of 18.37 mL and 0.77 billion cells.
CGT Global’s published table reports an average volume of 185.17 mL and an average total nucleated cell count of 15.07 billion. These are reported averages, rather than guaranteed minimum specifications for every collection.
View Full-Size Cell-Count Table →

Mobilized Leukopak Cell Counts & CD34+ Percentages

Mobilized leukopak averages chart comparing total nucleated cell counts and CD34-positive cell percentages across plerixafor, G-CSF, and combination mobilization methods.
Published comparison of total nucleated cell counts and CD34+ cell percentages across the mobilization methods shown. Discuss the collection regimen and target cell requirements appropriate for your project.
View Full-Size Mobilized Leukopak Chart →

Representative Flow Data for Enriched CD34+ Cells

Representative flow cytometry plots showing viability and CD34-positive purity of enriched cells from mobilized peripheral blood before cryopreservation.
Representative viability and purity analysis of enriched CD34+ cells from mobilized peripheral blood before cryopreservation. This figure characterizes an enriched cell population; it does not describe whole-leukopak purity or post-thaw performance.
View Full-Size Flow Data →

Need product-specific specifications? Cell counts, composition, viability, and processing requirements vary by product and collection. Request the applicable product documentation and discuss your target cell population with our team.

Request Specifications & Availability

From Collection to Your Next Experiment

Leukopak Applications & Cell Isolation

Leukopaks provide a concentrated starting material for workflows requiring multiple immune cell populations or larger cell quantities. Product suitability depends on the target cells, donor characteristics, processing method, and downstream assay.

NK-Cell & Immune Studies

Support NK-cell isolation, cytotoxicity assays, immune profiling, and studies of interactions between immune cell populations.

Explore Human PBMCs →

Bulk & Custom Isolation

Discuss PBMC isolation, selected immune populations, or bulk single-donor material when your project needs a defined cell population.

Explore CellsExpress →

Understand Your Options

Leukopaks, PBMCs or Isolated Cells?

A leukopak is a leukapheresis collection enriched in white blood cells. It provides starting material that can be processed into PBMCs or selected cell populations. It is not the same as an already isolated, purified cell product.

PBMC products provide a mixed mononuclear cell population, including lymphocytes and monocytes. Isolated cell products provide a selected population for a more targeted workflow.

Choose based on the cells and quantity required, your processing capacity, and how much preparation you want to perform in your own laboratory.

Frequently Asked Questions

Questions About Human Leukopaks

What is a leukopak?

A leukopak is a concentrated white blood cell product collected by leukapheresis. It contains a mixed cell population that can be used as starting material for PBMC preparation and immune cell isolation.

What cell types are found in leukopaks?

Leukopaks contain immune populations such as T cells, B cells, NK cells, and monocytes. Cell composition varies by donor, collection approach, and product. Mobilized collections are relevant when a workflow requires hematopoietic stem and progenitor cells.

What is the difference between fresh and cryopreserved leukopaks?

Fresh leukopaks require processing coordinated with collection and delivery. Cryopreserved leukopaks are frozen for storage and later use. The right format depends on your workflow, scheduling needs, and applicable product specifications.

How many cells are in a leukopak?

Cell quantity depends on the selected product, size, donor, and collection. Review the current product specifications and confirm whether a reported count refers to total nucleated cells, PBMCs, or a particular cell subset.

What is the difference between mobilized and non-mobilized leukopaks?

Mobilized leukopaks are collected after a donor receives a mobilizing agent to increase circulating hematopoietic stem and progenitor cells. Non-mobilized collections do not use that mobilization step. Select the collection approach based on your target population and protocol.

Can I request a specific donor profile or repeat donor?

CGT Global can evaluate donor criteria such as demographics, HLA typing, CMV status, and clinical characteristics. Recall and repeat-collection requests depend on donor availability, eligibility, and scheduling.

Do leukopaks require additional processing?

Processing depends on the selected product and the cells your workflow requires. Leukopaks are mixed starting material; PBMC enrichment, red cell removal, or targeted cell isolation may be appropriate for your protocol. Discuss processing needs before ordering.

Are all leukopaks suitable for clinical manufacturing?

Product grade and suitability vary. Research-use products and GMP starting material have different intended uses and documentation requirements. Discuss your manufacturing program and quality requirements before selecting a product.

What is the difference between research-use and GMP clinical leukopaks?

Research-use leukopaks support laboratory studies and development workflows. GMP clinical leukopak options are intended for programs with defined manufacturing, quality, and documentation requirements. Discuss your intended use, donor eligibility, testing, and traceability requirements with CGT Global before selecting a product.

Can CGT Global isolate cells from a leukopak?

CGT Global can evaluate custom and bulk isolation projects through CellsExpress, including selected immune populations and project-specific processing. Provide the target population, quantity, donor criteria, and format for a feasibility review.

How do I request leukopak pricing and delivery information?

Send the product format, required quantity, donor criteria, testing needs, shipping destination, and requested timeline. Our team can evaluate available material and collection options and provide a quote.

Plan Your Next Collection

Let’s Find the Right Leukopak for Your Project

Tell us which cells you need, the quantity, donor criteria, and timeline. CGT Global can help evaluate product availability, collection options, and custom processing.

Request Leukopak Availability and Pricing